 |
 |
|
|
|
| Dutasteride |
 |
| Dutasteride |
 |
| 164656-23-9 |
 |
Dutasteride
(Skype:sales09_109)
Description:
Alias: Avodart
Duagen
CAS NO: 164656-23-9
MF: C27H30F6N2O2
MW: 528.53
Purity: 99%
Appearance:white powder.
Details:
Dutasteride is used alone or with another medication (tamsulosin [Flomax]) to treat benign prostatic hyperplasia (BPH
enlargement of the prostate gland). Dutasteride is used to treat symptoms of BPH and may reduce the chance of developing acute urinary retention (sudden inability to urinate). Dutasteride may also decrease the chance that prostate surgery will be needed. Dutasteride is in a class of medications called 5-alpha reductase inhibitors. It works by blocking the production of a natural substance that enlarges the prostate.
Applications:
Dutasteride (trademark name Avodart) is a dual 5-¥á reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Used for benign prostatic hyperplasia
however, it increases the risk of erectile dysfunction and decreased sexual desire.
Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH)
colloquially known as an "enlarged prostate".
In those who are being regularly screened 5-alpha-reductase inhibitor (finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
This class of medications increases rates of erectile dysfunction (with between 5% and 9% developing problems after starting their use). This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug.
The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer. While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
Dutasteride comes as a capsule to take by mouth. It is usually taken once a day with or without food. Take dutasteride at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dutasteride exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Email:sales09 at ycphar dom com
Skype:sales09_109
Telephone:86-027-50756084
Mobile:86-18872220656
|
 |
Dutasteride
(Skype:sales09_109)
Description:
Alias: Avodart
Duagen
CAS NO: 164656-23-9
MF: C27H30F6N2O2
MW: 528.53
Purity: 99%
Appearance:white powder.
Details:
Dutasteride is used alone or with another medication (tamsulosin [Flomax]) to treat benign prostatic hyperplasia (BPH
enlargement of the prostate gland). Dutasteride is used to treat symptoms of BPH and may reduce the chance of developing acute urinary retention (sudden inability to urinate). Dutasteride may also decrease the chance that prostate surgery will be needed. Dutasteride is in a class of medications called 5-alpha reductase inhibitors. It works by blocking the production of a natural substance that enlarges the prostate.
Applications:
Dutasteride (trademark name Avodart) is a dual 5-¥á reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Used for benign prostatic hyperplasia
however, it increases the risk of erectile dysfunction and decreased sexual desire.
Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH)
colloquially known as an "enlarged prostate".
In those who are being regularly screened 5-alpha-reductase inhibitor (finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
This class of medications increases rates of erectile dysfunction (with between 5% and 9% developing problems after starting their use). This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug.
The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer. While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
Dutasteride comes as a capsule to take by mouth. It is usually taken once a day with or without food. Take dutasteride at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dutasteride exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Email:sales09 at ycphar dom com
Skype:sales09_109
Telephone:86-027-50756084
Mobile:86-18872220656
|
|
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
